YOKNEAM ILIT, Israel and MARLBOROUGH, Mass., Aug. 14, 2018 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (Nasdaq: RWLK) today announced its financial results for the three- and six-months ended June 30, 2018.
Highlights of and subsequent to the second quarter include:
- Total revenue for the second quarter of 2018 was $1.8 million compared to $1.6 million in the prior quarter;
- 21 units were placed during the second quarter of 2018;
- The U.S. Department of Veterans Affairs (“VA”) updated its national policy to provide expanded access to ReWalk exoskeletons with additional VA sites and also including private rehabilitation clinics through the Veterans Choice Program;
- ReWalk received the first tranche of $5 million as part of a $20 million investment agreement with Timwell Corporation Limited, a Hong Kong entity, following shareholder approval;
- All five leading stroke rehabilitation centers began enrolling patients in ReWalk’s ReStore clinical study;
- ReWalk extended its agreement with the Wyss Institute at Harvard University to June 2022 to complete additional research programs for its groundbreaking soft exo-suit; and
- ReWalk Personal 6.0 exoskeleton added to the official German list of medical aids, becoming the first exoskeleton device included in the list.
“With several catalysts to drive growth in the sales of ReWalk Personal systems and a significant opportunity to deliver longer term value with our Restore technology, we believe we have a solid platform for growth. The VA Choice Program substantially broadens the geographic coverage area for veterans to the 137 VA and private ReWalk certified training centers across the U.S., which we believe will result in more veterans procuring ReWalk systems. And, with the addition of a formal reimbursement code in Germany, we expect to see faster processing times and additional referrals come through in the months ahead. Our Restore clinical study is underway at five of the leading stroke rehabilitation centers in the country and we are planning a mid-2019 commercial launch of the Restore, pending CE and FDA clearance,” stated Larry Jasinski, Chief Executive Officer of ReWalk.
Second Quarter 2018 Financial Results
Total revenue was $1.8 million for the second quarter of 2018, compared to $1.6 million in the first quarter of 2018 and $2.0 million during the prior year quarter. 21 ReWalk systems were placed during the second quarter of 2018, compared to 23 ReWalk systems placed in the prior quarter and 31 systems in the prior year period. 13 systems were placed in the U.S. and 8 were placed in our direct markets in Europe.
Gross margin improved to 43% during the second quarter of 2018 compared to 37% in the second quarter of 2017, primarily attributable to sales mix and lower product costs.
Total operating expenses in the second quarter of 2018 were $6.0 million compared to $6.1 million in the prior year period.
Net loss was $5.8 million for the second quarter of 2018 compared to a net loss of $6.3 million in the second quarter of 2017. Non-GAAP net loss for the first quarter was $4.7 million compared with a non-GAAP net loss of $4.9 million in the second quarter of 2017. A reconciliation of net loss to non-GAAP net loss is included at the end of this press release.
Liquidity
As of June 30, 2018, ReWalk had $9.1 million in cash on its balance sheet.
Guidance
The Company is updating its full year 2018 revenue guidance and now expects revenues at the lower end of its previously announced range of $9.0 to $11.0 million, depending on timing of reimbursement coverage.
About ReWalk Robotics Ltd.
ReWalk Robotics Ltd. develops, manufactures and markets wearable robotic exoskeletons for individuals with lower limb disabilities as a result of spinal cord injury or stroke. ReWalk’s mission is to fundamentally change the quality of life for individuals with lower limb disability through the creation and development of market leading robotic technologies. Founded in 2001, ReWalk has headquarters in the U.S., Israel and Germany. For more information on the ReWalk systems, please visit www.rewalk.com.

